Table 1.
Treatment‐related adverse events by treatment in the population of the three centers of Paris, Lyon, and Toulouse
| Adverse event | RT + temozolomide (n = 72), n (%) | RT + PCV (n = 67), n (%) | Total (n = 139), n (%) | p value |
|---|---|---|---|---|
| Dose decrease due to toxicity | 13 (23.2) | 54 (87.1) | 67 (56.8) | <.0001 |
| Missing | 16 | 5 | 21 | |
| Treatment discontinuation due to toxicity | 22 (39.5) | 47 (75.8) | 69 (58.5) | <.0001 |
| Missing | 16 | 5 | 21 | |
| All toxicities | ||||
| All grades | 37 (63.8) | 60 (100) | 97 (82.2) | <.0001 |
| Grade ≥3 | 5 (8.6) | 28 (46.7) | 33 (28.0) | <.0001 |
| Missing | 14 | 7 | 21 | |
| Hepatotoxicity | ||||
| All grades | 5 (8.9) | 19 (33.9) | 24 (21.4) | .0013 |
| Grade ≥3 | 0 (0.0) | 11 (19.6) | 11 (9.8) | .0005 |
| Missing | 16 | 11 | 27 | |
| Hematotoxicity | ||||
| All grades | 21 (36.2) | 52 (86.7) | 73 (61.9) | <.0001 |
| Grade ≥3 | 3 (5.2) | 16 (26.7) | 19 (16.1) | .0015 |
| Missing | 14 | 7 | 21 | |
| Nausea/vomiting | ||||
| All grades | 11 | 8 | 19 | |
| Grade ≥3 | 0 | 0 | 0 | |
| Neuropathy | ||||
| All grades | 0 | 16 | 16 | |
| Grade ≥3 | 0 | 2 | 2 | |
| Asthenia | ||||
| All grades | 8 | 5 | 13 | |
| Grade ≥3 | 1 | 0 | 1 | |
| Anaphylaxy | ||||
| All grades | 3 | 9 | 12 | |
| Grade ≥3 | 0 | 1 | 1 | |
| Constipation | ||||
| All grades | 0 | 4 | 4 | |
| Grade ≥3 | 0 | 0 | 0 | |
| Pain | ||||
| All grades | 0 | 5 | 5 | |
| Grade ≥3 | 0 | 0 | 0 |
Abbreviations: PCV, procarbazine, lomustine, and vincristine; RT, radiotherapy.